Skip to main content
Clinical Trials/NL-OMON36745
NL-OMON36745
Not yet recruiting
Phase 4

Is antibiotic treatment associated with reduced risk of a subsequent exacerbation and mortality in chronic obstructive lung disease? A randomized clinical trial. - TEXACOLD trial

Academisch Medisch Centrum0 sites2,000 target enrollmentTBD

Overview

Phase
Phase 4
Intervention
Not specified
Conditions
Exacerbation COPD
Sponsor
Academisch Medisch Centrum
Enrollment
2000
Status
Not yet recruiting
Last Updated
last year

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
TBD
End Date
TBD
Last Updated
last year
Study Type
Interventional

Investigators

Eligibility Criteria

Inclusion Criteria

  • Eligible for the cohort are patients aged \>\= 45 years, with a smoking history of \> 10 packyears and GOLD stage 1, 2 or 3; i.e. a post\-bronchodilator forced expiratory volume in one second (FEV1\)/forced vital capacity (FVC) ratio \< 0\.7, and FEV1 \> 30% \[30].
  • Patients will be included who had at least one documented episode of exacerbation during the past 3 years, with the restriction that treatment of the last exacerbation ended at least 4 week prior to inclusion in the study, and that symptoms returned to patient\*s baseline level.;In case of an exacerbation, patients will be randomized between doxycyclin 100 mg daily (1st day 200 mg), for 7 days, or placebo.

Exclusion Criteria

  • Excluded are patients with
  • \- poor cognitive functioning,
  • \- poor mastering of the Dutch language,
  • \- allergy for doxycyclin,
  • \- pregnancy,
  • \- a life expectancy less than one month.;In case of an exacerbation, patients will be randomized between doxycyclin and placebo.
  • Not eligible for randomization are patients
  • who should be treated with antibiotics according to the Dutch College of General Practitioners' guidelines for diagnosis and treatment of COPD and the Dutch multidisciplinary guideline for medical treatment of COPD (2008, NVALT/NHG): in case of symptoms of clinical infection (body temperature \> 38\.5C), or a low baseline expiratory flow rate (FEV1 \< 30%) \[21,42].
  • Patients who require hospitalization according to the ATS/ERS criteria \[44], who also should receive antibiotics.
  • Who currently use antibiotic therapy (including maintenance therapy).

Outcomes

Primary Outcomes

Not specified

Similar Trials